GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'BRSR '.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GSK Pharmaceuticals has filed its mandatory Business Responsibility and Sustainability Report (BRSR) for FY 2024-25 with BSE and NSE, covering ESG performance across all 9 NGRBC principles. Key financials disclosed include turnover of INR 3,72,349 lakhs, net worth of INR 1,94,923 lakhs, and CSR spending of INR 1,603.84 lakhs (2% of average net profits), reaching 41,400+ beneficiaries. The company operates 1 manufacturing plant (Nashik), 5 offices, and serves customers through 5,706 dealers (up from 4,317 last year), with total workforce of 3,140. Environmentally, capex on green technologies rose to 41% (from 30% in FY23-24), CO2 reduction hit 6.4% beating the 5% target, though energy reduction of 3.1% fell short of the 8% goal. The report notes no fines, penalties, or disciplinary actions on bribery/corruption, and reasonable assurance was provided by Bureau Veritas India.
This is a routine annual regulatory compliance filing under SEBI LODR regulations and is unlikely to move the stock. It reinforces GSK India's strong ESG credentials and operational stability, but highlights some areas where sustainability targets were missed (energy reduction), which long-term ESG-focused investors may note.